(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Clinical trial NCT03731260 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03731260
- Sponsor
- Blueprint Medicines Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-16
- Primary completion
- 2027-06-23
- Enrollment
- 251
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.